| 產(chǎn)品名稱 | Baricitinib - INCB 028050 | LY 3009104 |
| 產(chǎn)品貨號 | Axon 1955 CAS [1187594-09-7] MF C16H17N7O2SMW 371.42 Purity: 99% Soluble in 0.1N HCl(aq) and DMSO Description Selective and orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM); INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concentrations <50 nM References Certificates Categories Extra info JS Fridman et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J. Immunol. 2010, 184(9), 5298-5307.? Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology Epigenetics Immunology Pain & Inflammation JAK-STAT EC 2.7.10.2 JAK Inhibitor of JAK1 and JAK2 Chemical name 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile Parent CAS No. [1187594-09-7] Order Size Unit Price Stock 5 mg €90.00 In Stock |
| 產(chǎn)品價格 | 現(xiàn)貨詢價，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
Baricitinib - INCB 028050 | LY 3009104Axon 1955 CAS [1187594-09-7] MF C16H17N7O2S
Description
Selective and orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM); INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concentrations <50 nM
Inhibitor of JAK1 and JAK2
Chemical name2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile Parent CAS No.[1187594-09-7] |
| 產(chǎn)品資料 |
